Quarter
Charts
🇺🇸US Markets

NeoGenomics, Inc.

NEO

CIK 0001077183 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$190M
↑+10.6% +$18Mvs FY2024 (Q4)
Operating Income
$65M
↑+9.8% +$6Mvs FY2024 (Q4)
Net Income
$65M
↑+11.9% +$7Mvs FY2024 (Q4)
Gross Profit
$83M
↑+7.9% +$6Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
43/100
  • Profitability
    0ROIC -7.8% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 4.26 (above 1.5 = solid)
  • Leverage
    80D/E 0.41 (under 0.5 = conservative)
  • Efficiency
    26Asset Turnover 0.53x (1.0+ = capital-efficient)
  • Growth
    52Revenue YoY +10.6% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -14.4% · trend -3.9pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$27M
investment in PP&E
Stock-based comp (TTM)
$41M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$1.36B
everything owned
Total liabilities
$523M
everything owed
Stockholders' equity
$837M
shareholder claim
Net debt
$182M
LT debt minus cash

Recent performance · 63 quarters

Revenue↑+10.6% +$18M
$190M
Net Income↓-53.3% -$9M
$-27M
Free Cash Flow↓-262.9% -$5M
$-7M
Operating Margin↓-1.8pts
-14.4%

Drill down